A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer
作者： Athanasios G. Pallis , Athina Agelidou , Pavlos Papakotoulas , Aimilia Tsaroucha , Maria Agelidou
DOI: 10.1016/J.LUNGCAN.2006.01.005
关键词: Phases of clinical research 、 Gastroenterology 、 Medicine 、 Survival rate 、 Regimen 、 Lung cancer 、 Surgery 、 Progressive disease 、 Internal medicine 、 Vinorelbine 、 Docetaxel 、 Gemcitabine
摘要: Summary Purpose To evaluate the activity and toxicity of sequential administration vinorelbine/cisplatin (VC regimen) followed by docetaxel/gemcitabine (DG combination in patients with advanced non-small cell lung cancer (NSCLC). Patients treatment Fifty-nine previously untreated advanced/metastatic NSCLC received three cycles cisplatin 80mg/m 2 (day 1), vinorelbine 30mg/m (days 1 8 every 3 weeks; VC regimen), six docetaxel (65mg/m , day 1) gemcitabine (1500mg/m weeks. Results One (1.7%) complete 26 (44.1%) partial responses were achieved for an overall response rate 45.8% (95% CI 33.05–58.48%); 12 (20.3%) had stable disease 20 (33.9%) progressive disease. The median time to progression was 5.3 months, survival 12.5 months 1-year 51%. main grade III/IV neutropenia occurring 25.5% patients; all other hematologic non-hematologic toxicities relatively infrequent. Conclusions DG regimens well tolerated active against merits be further evaluated a single doublet.
elsevier.com
sci-hub.se 参考文章(42)
Mark A Socinski, Michael J Schell, Amy Peterman, Kamal Bakri, Steven Yates, Robert Gitten, Paul Unger, Joanna Lee, Ji-Hyun Lee, Maureen Tynan, Martha Moore, Merrill S Kies, Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 20, pp. 1335- 1343 ,(2002) , 10.1200/JCO.20.5.1335
J.P. Bernard, P.J. Souquet, J.P. Boissel, F. Chauvin, R. Cellerino, D. Tumarello, Y. Cormier, P.A. Ganz, S. Kaasa, J.L. Pater, E. Quoix, E. Rapp, J. Williams, B.L. Woods, Polychemotherapy in advanced non-small cell lung cancer : a meta-analysis The Lancet. ,vol. 342, pp. 19- 21 ,(1993) , 10.1016/0140-6736(93)91882-M
Francesco Grossi, Ornella Belvedere, Gianpiero Fasola, Fabio Barbone, Simona Rizzato, Angela Sibau, Leonardo Recchia, Enrico Vigevani, Tino Ceschia, Angelo Morelli, Alessandra Guglielmi, Fabio Puglisi, Alessandro Follador, Giovanni Talmassons, Alberto F. Sobrero, Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001) Lung Cancer. ,vol. 46, pp. 99- 106 ,(2004) , 10.1016/J.LUNGCAN.2004.03.003
J.-Y Douillard, J Eckardt, G.V Scagliotti, Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer. ,vol. 38, pp. 21- 28 ,(2002) , 10.1016/S0169-5002(02)00168-X
Paris Kosmidis, Nick Mylonakis, Costas Nicolaides, Charalabos Kalophonos, Epaminontas Samantas, John Boukovinas, George Fountzilas, Dimosthenis Skarlos, Theophanis Economopoulos, Dimitrios Tsavdaridis, Pavlos Papakostas, Charalabos Bacoyiannis, Meletios Dimopoulos, Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial Journal of Clinical Oncology. ,vol. 20, pp. 3578- 3585 ,(2002) , 10.1200/JCO.2002.12.112
David Collett, Modelling Survival Data in Medical Research ,(1993)
V. Westeel, E. Quoix, D. Moro-Sibilot, M. Mercier, J.-L. Breton, D. Debieuvre, P. Richard, M.-A. Haller, B. Milleron, D. Herman, M.-C. Level, F.-X. Lebas, M. Puyraveau, A. Depierre, , Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 499- 506 ,(2005) , 10.1093/JNCI/DJI096
A. B. Miller, B. Hoogstraten, M. Staquet, A. Winkler, Reporting results of cancer treatment Cancer. ,vol. 47, pp. 207- 214 ,(1981) , 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Vassilis Georgoulias, Charalambos Kouroussis, Nikos Androulakis, Stelios Kakolyris, Meletios-Athanasios Dimopoulos, Emmanuel Papadakis, Dimosthenis Bouros, Fotini Apostolopoulou, Christos Papadimitriou, Athina Agelidou, Kostas Hatzakis, Kostas Kalbakis, Athanasios Kotsakis, Nikos Vardakis, John Vlachonicolis, Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial Journal of Clinical Oncology. ,vol. 17, pp. 914- 920 ,(1999) , 10.1200/JCO.1999.17.3.914
J Feliu, G Martin, J Lizon, JI Chacon, J Dorta, J de Castro, A Rodriguez, B Sánchez Heras, JC Torrego, E Espinosa, M González Barón, Oncopaz Cooperative Group, Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin—gemcitabine—vinorelbine. A phase II study Annals of Oncology. ,vol. 12, pp. 1369- 1374 ,(2001) , 10.1023/A:1012552525667